Search

Your search keyword '"Lipuma JJ"' showing total 308 results

Search Constraints

Start Over You searched for: Author "Lipuma JJ" Remove constraint Author: "Lipuma JJ"
308 results on '"Lipuma JJ"'

Search Results

1. Model Systems to Study the Chronic, Polymicrobial Infections in Cystic Fibrosis: Current Approaches and Exploring Future Directions

2. Cystic Fibrosis Mice Develop Spontaneous Chronic Bordetella Airway Infections

4. Future directions in early cystic fibrosis lung disease research: an NHLBI workshop report.

5. Rhinovirus infection liberates planktonic bacteria from biofilm and increases chemokine responses in cystic fibrosis airway epithelial cells.

6. Impact of Burkholderia dolosa on lung function and survival in cystic fibrosis.

10. Frameshift Mutations in Genes Encoding PBP3 and PBP4 Trigger an Unusual, Extreme β-Lactam Resistance Phenotype in Burkholderia multivorans .

11. Assessing effectiveness of cleaning and disinfection of equipment and environmental surfaces in cystic fibrosis clinics using an ATP assay.

12. Burkholderia multivorans Infections Associated with Use of Ice and Water from Ice Machines for Patient Care Activities - Four Hospitals, California and Colorado, 2020-2024.

13. Source-to-tap investigation of the occurrence of nontuberculous mycobacteria in a full-scale chloraminated drinking water system.

14. Practical Guidance for Clinical Microbiology Laboratories: Updated guidance for processing respiratory tract samples from people with cystic fibrosis.

15. A Comparative Metagenomic Analysis of Specified Microorganisms in Groundwater for Non-Sterilized Pharmaceutical Products.

16. Investigating the suitability of online flow cytometry for monitoring full-scale drinking water ozone system disinfection effectiveness.

17. Microbial community organization designates distinct pulmonary exacerbation types and predicts treatment outcome in cystic fibrosis.

18. Novel Ralstonia species from human infections: improved matrix-assisted laser desorption/ionization time-of-flight mass spectrometry-based identification and analysis of antimicrobial resistance patterns.

19. Prevalence and Clinical Impact of Respiratory Viral Infections from the STOP2 Study of Cystic Fibrosis Pulmonary Exacerbations.

20. Association of Pseudomonas aeruginosa incident infections with adherence to cystic fibrosis foundation care guidelines.

21. Quantifying variation in home spirometry in people with cystic fibrosis during baseline health, and associations with clinical outcomes.

22. Longitudinal bacterial prevalence in cystic fibrosis airways: Fact and artifact.

23. Examining the activity of cefepime-taniborbactam against Burkholderia cepacia complex and Burkholderia gladioli isolated from cystic fibrosis patients in the United States.

24. Microbial community organization designates distinct pulmonary exacerbation types and predicts treatment outcome in cystic fibrosis.

25. Airway bacterial community composition in persons with advanced cystic fibrosis lung disease.

26. Phage therapy in a lung transplant recipient with cystic fibrosis infected with multidrug-resistant Burkholderia multivorans.

27. Characterizing Biofilm Interactions between Ralstonia insidiosa and Chryseobacterium gleum .

28. Activity of ETX0462 toward Some Burkholderia spp.

29. Outbreak of Burkholderia stabilis Infections Associated with Contaminated Nonsterile, Multiuse Ultrasound Gel - 10 States, May-September 2021.

30. Shower water contributes viable nontuberculous mycobacteria to indoor air.

31. Outbreak of Burkholderia contaminans endophthalmitis traced to a clinic ventilation system.

33. The Sense and Nonsense of Antimicrobial Susceptibility Testing in Cystic Fibrosis.

34. Changes in airway bacterial communities occur soon after initiation of antibiotic treatment of pulmonary exacerbations in cystic fibrosis.

35. The Class A β-Lactamase Produced by Burkholderia Species Compromises the Potency of Tebipenem against a Panel of Isolates from the United States.

36. Clinical challenges treating Stenotrophomonas maltophilia infections: an update.

38. Association of bacterial community types, functional microbial processes and lung disease in cystic fibrosis airways.

39. Genomic heterogeneity underlies multidrug resistance in Pseudomonas aeruginosa: A population-level analysis beyond susceptibility testing.

40. Mechanism of Action and Resistance Evasion of an Antimicrobial Oligomer against Multidrug-Resistant Gram-Negative Bacteria.

41. Fourier Transform Infrared Spectroscopy for Typing Burkholderia cenocepacia ET12 Isolates.

42. Evaluation of Antimicrobial Susceptibility Testing Methods for Burkholderia cenocepacia and Burkholderia multivorans Isolates from Cystic Fibrosis Patients.

43. Model Systems to Study the Chronic, Polymicrobial Infections in Cystic Fibrosis: Current Approaches and Exploring Future Directions.

44. Activity of Imipenem-Relebactam against Multidrug- and Extensively Drug-Resistant Burkholderia cepacia Complex and Burkholderia gladioli.

45. Impact of the SARS-CoV-2 pandemic on cystic fibrosis centres and care: survey results from US centres.

46. Loop-Mediated Isothermal Amplification (LAMP) Assay for Detecting Burkholderia cepacia Complex in Non-Sterile Pharmaceutical Products.

47. Cystic fibrosis airway microbiota associated with outcomes of nontuberculous mycobacterial infection.

48. Environmental and clinical isolates of Herbaspirillum induce pulmonary infection in mice and its secretome is cytotoxic to human lung cells.

49. Clinical characteristics and outcomes associated with Inquilinus infection in cystic fibrosis.

50. In Vitro Antibacterial Activity and In Vivo Efficacy of Sulbactam-Durlobactam against Pathogenic Burkholderia Species.

Catalog

Books, media, physical & digital resources